Abortion

The Supreme Court’s decision to overturn Roe v. Wade and subsequent state abortion bans have moved the issue of access to high-quality and affordable contraceptive care to the forefront. As these seismic shifts shape women’s health care in the United States, the FDA is considering an application for a daily…

This policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.

In anticipation of a ruling in a case with enormous implications for access to medication abortion in the United States, a new KFF brief explains the impact of this case, and others filed in federal courts, involving the FDA’s regulation of medication abortion. The case that has gotten the most…

This issue brief details the Alliance of Hippocratic Medicine challenge to the FDA’s approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.

Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000,…

KFF has created two new trackers to follow swift-moving reproductive rights litigation in the state and federal courts. The tools, which are currently tracking the status of 21 state cases in 15 states and eight federal cases, will be updated regularly as the litigation proceeds. Major cases pending in federal…

This State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.

A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to…

This issue brief examines the varying exceptions (for life, health, rape/incest, and fatal fetal anomalies) in state abortion bans and restrictions and the complications that arise when pregnant people attempt to access abortion care under these exceptions.

This policy watch explains the April 21, 2023 United States Supreme Court’s ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA’s approval of mifepristone, the medication abortion pill.